Geoffrey Mackay - 02 Feb 2022 Form 4 Insider Report for AVROBIO, Inc. (TECX)

Role
President & CEO, Director
Signature
/s/ Christopher Gerry, Attorney-in-Fact for Geoffrey MacKay
Issuer symbol
TECX
Transactions as of
02 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 16:22:33 UTC
Previous filing
14 Jun 2021
Next filing
13 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVRO Stock Option (Right to Buy) Award $0 +405,000 $0.000000 405,000 02 Feb 2022 Common Stock 405,000 $1.84 Direct F1
transaction AVRO Stock Option (Right to Buy) Award $0 +328,500 $0.000000 328,500 02 Feb 2022 Common Stock 328,500 $1.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period.